What is Tactus Technology?
Tactus Technology is the developer of GloTran, a sophisticated low-temperature gas plasma disinfection system designed to address the rigorous demands of modern clinical environments. The platform is engineered to treat non-critical medical devices, providing a robust mechanism for improving infection control practices within hospitals and surgical centers. By utilizing advanced plasma technology, the system offers a high-efficacy alternative to traditional sterilization methods, effectively mitigating the risk of healthcare-associated infections.
The company occupies a vital niche in the medical device sector, where the demand for rapid, safe, and reliable decontamination is at an all-time high. Through its focus on low-temperature applications, Tactus Technology enables the safe processing of heat-sensitive equipment, thereby extending the lifecycle of medical assets while maintaining the highest standards of patient safety and regulatory compliance.
How much funding has Tactus Technology raised?
Tactus Technology has raised a total of $6.3M across 2 funding rounds:
Series A
$6M
Debt
$302K
Series A (2011): $6M with participation from Thomvest Ventures
Debt (2021): $302K led by PPP
Key Investors in Tactus Technology
Thomvest Ventures
Thomvest is a group of investment companies that invests on behalf of Peter J. Thomson and his family, focusing on supporting exceptional entrepreneurs to build industry-defining companies. The firm specializes in sectors such as proptech and fintech, offering deep industry expertise and a robust network of resources.
PPP
Public-Private Partnership
What's next for Tactus Technology?
With the recent influx of capital, Tactus Technology is poised to scale its commercial operations and deepen its penetration into the global hospital market. The strategic deployment of these funds will likely prioritize the expansion of manufacturing capabilities and the enhancement of the GloTran system's distribution network. As the healthcare industry continues to prioritize infection prevention, the company is well-positioned to capitalize on the increasing adoption of automated disinfection technologies.
Looking ahead, the firm will likely focus on clinical validation and regulatory milestones to further solidify its market position. By maintaining a disciplined approach to capital allocation, Tactus Technology aims to transition from a specialized technology provider to a standard-bearer in the medical device decontamination space, ultimately driving long-term value for its stakeholders and improving clinical outcomes for healthcare providers worldwide.
